Medicis Pharmaceutical Earnings Preview
Medicis Pharmaceutical (NYS: MRX) beat estimates by $0.01 last quarter, and investors are hoping it can beat them again. The company will unveil its latest earnings Tuesday Medicis Pharmaceutical focuses on helping patients attain a healthy and youthful appearance and self-image through the development and marketing in the U.S. of products for the treatment of dermatological and aesthetic conditions.
What analysts say:
- Buy, sell, or hold?: Analysts are bullish on this stock with 11 analysts rating it as a buy and only one rating it as a sell. Analysts like Medicis Pharmaceutical better than competitor Impax Laboratories overall. Analysts haven't adjusted their rating of Medicis Pharmaceutical for the past three months.
- Revenue forecasts: On average, analysts predict $188.8 million in revenue this quarter. That would represent a rise of 8.5% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is earnings of $0.64 per share. Estimates range from $0.61 to $0.67.
What our community says:
CAPS All-Stars are solidly behind the stock with 95.6% assigning it an "outperform" rating. The community at large concurs with the All-Stars with 93.2% awarding it a rating of "outperform." Fools are gung-ho about Medicis Pharmaceutical, though the message boards have been quiet lately with only 78 posts in the past 30 days. Despite the majority sentiment in favor of Medicis Pharmaceutical, the stock has a middling CAPS rating of three out of five stars.
Medicis Pharmaceutical's profit has risen year over year by an average of 20.2%. A year-over-year revenue decrease last quarter snaps a streak of three consecutive quarters of revenue increases.
We can help you keep tabs on your companies with My Watchlist, our free, personalized service. Add Medicis Pharmaceutical now.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
At the time this article was published
Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.